Physician profile
Mark D Rattinger
NPI 1104988195
$8,120.12
in general payments reported to CMS, 2019-2025
53 companies · $1,767 in 2025
The $1,767 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $277 · 2021: $910 · 2022: $1,123 · 2023: $1,505 · 2024: $1,328 · 2025: $1,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,482 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,482.11 |
| Education | $117.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,031.26 | 2019-2025 | |
| Amgen INC. | $826.17 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals Lp | $595.42 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $550.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $417.96 | 2021-2023 | |
| Exact Sciences Corporation | $355.98 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $332.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sumitomo Pharma America, INC. | $307.51 | 2023-2025 | Gemtesa, Myfembree |
| Glaxosmithkline, LLC. | $295.47 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $250.30 | 2019-2024 | Xarelto |
| Radius Health, INC. | $248.39 | 2023-2025 | Tymlos |
| Abbott Laboratories | $234.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.32 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $192.27 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $190.86 | 2019-2024 | Capvaxive |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rattinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.